Hims & Hers Faces Class Action Lawsuit Following FTC Misconduct Complaint

Key Facts

1Hims & Hers Health and certain executives are facing a securities class action lawsuit.

2The lawsuit follows an FTC federal complaint accusing the company of serious business misconduct.

In a move reflecting tightened regulatory oversight of digital healthcare firms, Hims & Hers Health and certain executives are facing a securities class action lawsuit. This legal action follows the unveiling of a federal complaint from the Federal Trade Commission (FTC) accusing the company of serious business misconduct. According to reports, the lawsuit alleges that these practices led to a sharp decline in the stock price, resulting in significant financial losses for shareholders.

The allegations center on claims that the company engaged in improper business practices, placing it under intense regulatory scrutiny. Based on the case facts, the revelation of the FTC's intervention erased a substantial portion of the company's market capitalization in a short period. This class action serves as a direct response to concerns regarding the transparency of financial and operational disclosures provided by management to investors.

Looking at stock performance, HIMS closed at $28.81 as of September 14, 2026, with price fluctuations between $27.14 and $29.44 during the trading session. Traders are currently monitoring how these legal developments will impact market confidence, as the immediate economic calendar shows no direct sector-related catalysts, leaving the legal proceedings as the primary driver for the stock in the near term.